Nautilus Biotechnology, Inc.
NAUTHeld by 1 specialist biotech fund
1 fund opened new positions. Short interest: 1.1% of float.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.